Skip to content
value.today

Metagenomi Technologies, LLC

Total raised
$345 M
5 rounds on record
Latest round
$96 M
Dec 2022
First round on record
Aug 2019
Today
Went public
See the company page

Metagenomi Technologies, LLC is listed today as Metagenomi Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Metagenomi Technologies, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$96 MNo. 5$50 to $250 million

Metagenomi Technologies, LLC: Raise no. 5, Dec 2022

Investors in this round

25 investors had bought by the notice of Jan 11, 2023: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Metagenomi Technologies, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$96 M of $100 M offered; $4 M still to sell
Smallest investment taken
$100,000
What was sold
equity, other: Series B-1 Preferred units
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Brian C. Thomas · Executive Officer, Director
  • Juergen C. Eckhardt · Director
  • Risa C. Stack · Director
  • Santhosh C. Palani · Director
  • Sebastian C. Bernales · Director
  • Willard C. Dere · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Thomas, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 11, 2023. Read the notice at the SEC.

equitySEC
Jan 2022$175 MNo. 4$50 to $250 million

Metagenomi Technologies, LLC: Raise no. 4, Jan 2022

Investors in this round

29 investors had bought by the notice of Feb 7, 2022: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Metagenomi Technologies, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$175 M of $175 M offered
Smallest investment taken
$1,000,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Brian Thomas · Executive Officer, Director · Manager
  • Juergen Eckhardt · Director · Manager
  • Risa Stack · Director · Manager
  • Santosh Palani · Director · Manager
  • Sebastian Bernales · Director · Manager
  • Willard Dere · Director · Manager

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Thomas, Ceo. Source: SEC Form D, newest notice filed Feb 7, 2022. Read the notice at the SEC.

equitySEC
Mar 2021$10 MNo. 3$10 to $50 million

Metagenomi Technologies, LLC: Raise no. 3, Mar 2021

Investors in this round

2 investors had bought by the notice of Mar 29, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Metagenomi Technologies, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Brian Thomas · Executive Officer, Director, Promoter
  • Andrew Farquharson · Director
  • Andrew Levin · Director
  • Juergen Eckhardt · Director
  • Sebastian Bernales · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Thomas, Ceo. Source: SEC Form D, newest notice filed Mar 29, 2021. Read the notice at the SEC.

equitySEC
Nov 2020$38 MNo. 2$10 to $50 million

Metagenomi Technologies, LLC: Raise no. 2, Nov 2020

Investors in this round

11 investors had bought by the notice of Nov 25, 2020: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Metagenomi Technologies, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $40 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Brian Thomas · Executive Officer, Director, Promoter
  • Andrew Farquharson · Director
  • Juergen Eckhardt · Director
  • Sebastian Bernales · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Thomas, Ceo. Source: SEC Form D, newest notice filed Nov 25, 2020. Read the notice at the SEC.

equitySEC
Aug 2019$26 MNo. 1$10 to $50 million

Metagenomi Technologies, LLC: Raise no. 1, Aug 2019

Investors in this round

16 investors had bought by the notice of Aug 16, 2019: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 5 investors are named for Metagenomi Technologies, LLC as a whole in other filings: see Investors below.

What the notice says

Amount sold
$26 M of $27 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Brian Thomas · Executive Officer, Director, Promoter
  • Andrew Farquharson · Director
  • Jak Knowles · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brian C. Thomas, Ceo. Source: SEC Form D, newest notice filed Aug 16, 2019. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Metagenomi Technologies, LLC chose not to state its revenue in its newest notice of a funding round (Jan 2023).

    SEC Form D · Jan 2023

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jan 2023

That is all the official record says: Metagenomi Technologies, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Metagenomi Technologies, LLC are on record.

Investors#

5 named in official filings. Open an investor to see everything it has backed.

Investors in Metagenomi Technologies, LLC
InvestorKindAmountRoundRoleSource
Bayer Healthcare LLCOthernot statednot statedHeld Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Bayer US Holding LPFund or asset managernot statednot statedHeld Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Bayer World Investments B.V.Fund or asset managernot statednot statedHeld Series A-1, A-4, B and B-1 preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series B and B-1 preferred stock, 10% owner (Form 3, 2024)SEC Form 3
Sebastian BernalesPersonnot statednot statedHeld Series A-2, A-3 and A-4 preferred stock, director (Form 3, 2024)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 29 investors.

Largest shareholders today

Institutions holding Metagenomi Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Metagenomi Technologies, LLC
NameRoleNamed in
Brian C. ThomasExecutive officerJan 2023
Brian ThomasManagerFeb 2022
Brian C. ThomasDirectorJan 2023
Juergen C. EckhardtDirectorJan 2023
Risa C. StackDirectorJan 2023
Santhosh C. PalaniDirectorJan 2023
Sebastian C. BernalesDirectorJan 2023
Willard C. DereDirectorJan 2023
Brian ThomasManagerFeb 2022
Juergen EckhardtManagerFeb 2022
Risa StackManagerFeb 2022
Santosh PalaniManagerFeb 2022
Sebastian BernalesManagerFeb 2022
Willard DereManagerFeb 2022
Andrew FarquharsonDirectorMar 2021
Andrew LevinDirectorMar 2021
Jak KnowlesDirectorAug 2019
Brian ThomasPromoterMar 2021

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.